1186486-62-3 | Evacetrapib (LY2484595)

Packsize	Purity	Availability	Price	Discounted Price
1mg	98%	in stock	$16.00	$11.00
5mg	98%	in stock	$39.00	$28.00
10mg	98%	in stock	$59.00	$41.00
100mg	98%	in stock	$555.00	$389.00

Description

• Catalog Number: AE11213
• Chemical Name: Evacetrapib (LY2484595)
• CAS Number: 1186486-62-3
• Molecular Formula: C32H37F6N5O2
• Molecular Weight: 637.6589
• MDL Number: MFCD23105886
• SMILES: OC(=O)[C@@H]1CC[C@H](CC1)CN1CCC[C@@H](c2c1c(C)cc(c2)C)C(c1nnn(n1)C)Cc1cc(cc(c1)C(F)(F)F)C(F)(F)F

Computed Properties

• Complexity: 973
• Covalently-Bonded Unit Count: 1
• Defined Atom Stereocenter Count: 1
• Heavy Atom Count: 45
• Hydrogen Bond Acceptor Count: 13
• Hydrogen Bond Donor Count: 1
• Rotatable Bond Count: 7
• XLogP3: 7.7

Literature

• Recent advances in pharmacotherapy for hypertriglyceridemia.

  Progress in lipid research 20141001

• Future of cholesteryl ester transfer protein inhibitors.

  Annual review of medicine 20140101

• Rationale for cholesteryl ester transfer protein inhibition.

  Current opinion in lipidology 20120801

• Evacetrapib.

  Current cardiology reports 20120601

• Design, synthesis and structure-activity-relationship of 1,5-tetrahydronaphthyridines as CETP inhibitors.

  Bioorganic & medicinal chemistry letters 20120501

• New focus on raising HDL 'good' cholesterol. But the value of this is not entirely clear.

  DukeMedicine healthnews 20120201

• Cholesteryl ester transfer protein inhibitors for dyslipidemia: focus on dalcetrapib.

  Drug design, development and therapy 20120101

• [Secondary coronary heart disease prevention. Will CEPT inhibitors be the next breakthrough?].

  MMW Fortschritte der Medizin 20111208

• Evacetrapib is a novel, potent, and selective inhibitor of cholesteryl ester transfer protein that elevates HDL cholesterol without inducing aldosterone or increasing blood pressure.

  Journal of lipid research 20111201

• Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial.

  JAMA 20111116

• High-density lipoprotein cholesterol as the Holy Grail.

  JAMA 20111116